The cord blood banking industry is a rapidly evolving industry experiencing nearly constant innovation. Every month there are major events that shift industry dynamics. Often, these events are announcements of technical or scientific advancements. Sometimes they are announcements of industry collaborations or alliances. Occasionally, they are announcements of a new industry competitor, a major milestone, or a significant grant award. [Read more…]
Induced Pluripotent Stem Cell News Round-Up| February 22 – 28, 2015
“Supreme Court Rules on Stem Cells, $100 Billion Proposed for International Stem Cell Collaboration, Japan to Launch iPSC Therapy Center, and More”
Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015.
[Read more…]
Induced Pluripotent Stem Cell (iPSC) News Round-Up| February 2015
“Supreme Court Rules on Stem Cells, $100 Billion Proposed for International Stem Cell Collaboration, Japan to Launch iPSC Therapy Center, and More”
Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015. [Read more…]
Induced Pluripotent Stem Cell (iSPC) News Round-Up| January 2015
The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area. Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]
Induced Pluripotent Stem Cell News Round-Up| February 15-22, 2015
The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area. Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]
